All sponsors

Agios Pharmaceuticals, Inc. $AGIO

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS12
PHASE 3 / 2-39
RECRUITING3
READOUTS ≤12 MONTHS0
READOUT SLIPPED >6 MO0%

Delay Index: of 8 active trials registered more than a year ago, 0 have moved their primary completion (readout) date by more than 6 months since first registration (median +2.4 months). See all sponsors →

Open Agios Pharmaceuticals, Inc. on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
AG-348
NCT03692052
P2Active, not recruitingThalassemia202020-08-20 (-15 mo)
Mitapivat
NCT04770753
P3Active, not recruitingNon-Transfusion-dependent Alpha-Thalassemia; Non-Transfusion-dependent Beta-Thalassemia1942023-11-13 (+3 mo)
ENERGIZE-T
NCT04770779
P3Active, not recruitingTransfusion-dependent Alpha-Thalassemia; Transfusion-dependent Beta-Thalassemia2582024-04-11 (+3 mo)
ACTIVATE-KidsT
NCT05144256
P3Active, not recruitingPediatric Pyruvate Kinase Deficiency; Pediatric Hemolytic Anemia492024-05-03 (-6 mo)
ACTIVATE-Kids
NCT05175105
P3Active, not recruitingPediatric Pyruvate Kinase Deficiency; Pediatric Hemolytic Anemia302024-12-13 (+2 mo)
Mitapivat
NCT05031780
P2/3Active, not recruitingSickle Cell Disease2862025-10-30 (+2 mo)
Tebapivat
NCT05490446
P2Active, not recruitingMyelodysplastic Syndromes872026-03-17 (+4 mo)
Tebapivat
NCT06924970
P2Active, not recruitingSickle Cell Disease592026-05-12
ENERGIZEKids
NCT07517133
P3RecruitingNon-Transfusion-dependent Alpha-Thalassemia; Non-Transfusion-dependent Beta-Thalassemia452029-03
ENERGIZEKids-T
NCT07506863
P3RecruitingTransfusion-dependent Alpha-Thalassemia; Transfusion-dependent Beta-Thalassemia542029-06
Mitapivat
NCT07656415
P3RecruitingSickle Cell Disease1592029-08
PreVail
NCT07859423
P2/3Not yet recruitingPolycythemia Vera2452030-08